In this Community Spotlight, Victoria Colone delves into the complexities of early diagnosis and treatment as a mom navigating the world of healthcare for her child with SMA. Victoria Colone was 22 weeks pregnant when she learned through an amniocentesis test that her son, Jaxon, had SMA Type I. Despite her OB/GYN and genetic counselor […]
Community Spotlight: The Colone Family Read More »
The 2018 SMA Standards of Care recommendations were published in Neuromuscular Disorders in February 2018 and March 2018 and are available online through Open Access for families and healthcare providers. These documents are updates of the Standard of Care document issued in 2007. The 2018 recommendations emphasize that “a multidisciplinary approach is the key element
Updated 2018 SMA Standards of Care Statements Available Online Read More »
Last night, Governor Bruce Rauner of Illinois signed SB 456, adding spinal muscular atrophy (SMA) to the state’s newborn screening panel. The bill adds Illinois to a number of states who have already adopted permanent SMA screening, including Missouri, Utah, Minnesota and Indiana. The legislation was sponsored by Senators Julie Morrison, Michael Connelly and Thomas
Illinois Adopts Permanent SMA Screening Read More »
The guest blog post below was written by Heather Tomko, sharing her experience in the Ms. Wheelchair USA 2018 pageant. She is the reigning Ms. Wheelchair USA in addition to being a public health researcher and masters student. Heather is a lifelong Pittsburgh resident and lives with SMA Type II. Being in a pageant is
Heather Tomko Crowned as Ms. Wheelchair USA 2018 Read More »
The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA and seeks to create open communication of early, unpublished data to accelerate the pace of research. The meeting also furthers research by building collaborations—including cross-disciplinary dialogue, partnerships, integration of new researchers and drug companies, and educational opportunities for junior
2018 SMA Researcher Meeting Summary: SMA Therapy Development Read More »
At 10 years old, Brynne Willis knew something was wrong; it was time for the Presidential Fitness Test required by public schools and she kept falling behind her peers. “I kept falling every time I tried to run and was the last to complete the one-mile run,” said Brynne. Worried about the cause of her
Community Spotlight: Brynne Willis Read More »
The SMA community officially recognizes August as Spinal Muscular Atrophy Awareness Month, an effort that Cure SMA has been coordinating since 1996. August is a great time to spotlight the work our community does year-round to raise awareness of and funds for SMA. In addition to our usual work – hosting and attending events, advocating
August is SMA Awareness Month! Read More »
The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA and seeks to create open communication of early, unpublished data to accelerate the pace of research. The meeting also furthers research by building collaborations—including cross-disciplinary dialogue, partnerships, integration of new researchers and drug companies, and educational opportunities for junior
2018 SMA Researcher Meeting Summary: Clinical Research Studies for SMA Read More »
The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA and seeks to create open communication of early, unpublished data to accelerate the pace of research. The meeting also furthers research by building collaborations—including cross-disciplinary dialogue, partnerships, integration of new researchers and drug companies, and educational opportunities for junior
2018 SMA Researcher Meeting Summary: Basic Research Podium Presentations Read More »
The SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA and seeks to create open communication of early, unpublished data to accelerate the pace of research. The meeting also furthers research by building collaborations—including cross-disciplinary dialogue, partnerships, integration of new researchers and drug companies, and educational opportunities for junior
